title: Updates on treatment of gemcitabine-refractory pancreatic adenocarcinoma. Highlights from the "2011 ASCO Annual Meeting". Chicago, IL, USA; June 3-7, 2011.
abstract: Gemcitabine monotherapy and gemcitabine-based regimens are the current standard of care for locally advanced or metastatic pancreatic adenocarcinoma. However, there is still great controversy over the role of salvage chemotherapy after failure of gemcitabine. This review is an update on the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting regarding the most important developments in the treatment of refractory pancreatic cancer, as they were reported in Abstracts #e14542 and #e14588.
authors: Oncology Unit, Third Department of Medicine, Sotiria General Hospital, Athens Medical School, Athens, Greece.
authors: Nektaria
authors: N
authors: Makrilia
authors: Kostas N
authors: KN
authors: Syrigos
authors: Muhammad W
authors: MW
authors: Saif
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy / Q000628:therapy*; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002641:Chicago; D003226:Congresses as Topic; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D019008:Drug Resistance, Neoplasm / Q000502:physiology; D006801:Humans; D008495:Medical Oncology / Q000379:methods; D008954:Models, Biological; D010190:Pancreatic Neoplasms / Q000188:drug therapy / Q000628:therapy*; D012955:Societies, Medical; D014481:United States; D000093542:Gemcitabine
chemical_list: D000970:Antineoplastic Agents; D003841:Deoxycytidine; D000093542:Gemcitabine